Chemicals giant Bayer announced Monday that it will produce from 2022 a coronavirus vaccine that fellow German pharmaceuticals company CureVac is developing.
"I am happy to tell you that we have the necessary capacities to produce CureVac's mRNA-based vaccine," Bayer's head of pharmaceuticals Stefan Oelrich told reporters, adding that the company aimed to produce 160 million doses in the first 12 months.
